HBIO earnings analysis
What we found in HBIO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Harvard Bioscience's Q2 2026 revenue increased to $22.727 million, up 8.1% sequentially and 13.6% year over year, while diluted EPS improved materially to negative $0.14 from negative $0.77 in Q1. Results exceeded consensus revenue and EPS estimates. However, the company remained unprofitable, and the provided 10-Q extract contains no segment, balance-sheet, cash-flow, margin, or quantitative guidance disclosures; risk factors were incorporated by reference to the December 31, 2025 Form 10-K.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Rebounded
- Q2 2026 revenue was $22.727 million, up from $21 million in Q1 2026 and $20 million in Q2 2025, representing sequential growth of approximately 8.1% and year-over-year growth of approximately 13.6%.
- EPS Loss Narrowed
- Diluted EPS improved to negative $0.14 from negative $0.77 in Q1 2026 and negative $0.50 in Q2 2025, although the company remained loss-making.
- Beat Revenue and EPS Estimates
- Revenue exceeded the $21.45 million consensus estimate by $1.277 million, or approximately 6.0%, while EPS of negative $0.14 was $0.01 better than the negative $0.15 estimate.
- Controls Remained Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal control that materially affected, or were reasonably likely to materially affect, financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Profitability Remains Negative
- The company continued to report a loss, with diluted EPS of negative $0.14 in Q2 2026. The filing also states that the risks in the December 31, 2025 Form 10-K remain applicable and that additional unknown or currently immaterial risks could materially adversely affect results.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.14
What they said about what is next.
The provided 10-Q text does not include quantitative revenue or EPS guidance. Recent media reports reference an increase to 2026 guidance, but no numeric outlook appears in the filing extract.
The filing reads better than the one before it.
What came before.
- 10-Q · May 12, 2026
- Harvard Bioscience's Q1 2026 results reflect continued challenges with revenue declining to $20.8 million, down from $21.8 million year-over-year, while EPS reached a loss of $0.77, significantly missing estimates.…
- 10-K · March 13, 2026
- Harvard Bioscience (HBIO) positions itself as a translational‑medicine enabler, aligning around Preclinical and CMT product families and targeting organoid/3D biology with new platforms (MeshMEA, Incub8, SoHo). 2025…
- 10-Q · November 6, 2025
- Harvard Bioscience reported Q3 2025 revenue of $20,591,000 (down from $21,970,000 in Q3 2024) and GAAP loss per share of $(0.03) compared with $(0.11) a year ago. Gross profit remained healthy at $12,021,000 and the…
- 10-Q · August 11, 2025
- Harvard Bioscience reported Q2 revenue of $20.45M and a GAAP net loss of $2.282M (loss per share $0.05). Gross margin remained healthy at 56.4% while the company recorded improved operating loss versus the prior-year…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing HBIO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever